INTRODUCTION
Acute kidney injury (AKI) had long been thought to be a completely reversible process, whereby resident kidney cells could repair the kidney after an ischemic or a toxic insult to fully restore renal function. During the last two decades, however, animal and human studies have linked AKI to chronic kidney disease (CKD) (1) (2) (3) (4) . CKD represents a worldwide health concern affecting more than 20 million Americans and about 10% of the global population, resulting in a rapidly increasing burden of associated cardiovascular diseases, end-stage kidney disease, mortality, and growing societal financial burden (5, 6) . Understanding the pathophysiology of CKD is of great importance to ultimately prevent and arrest its progression.
Injury causes tubular cells, especially proximal tubular cells (PTCs), to lose their polarity and brush border (7) , alters the location of membrane proteins such as -integrins (8, 9) , alters cell metabolism, induces DNA damage, and ultimately leads to cell death if the injury is sustained (10) . Tubular cells surviving after AKI are largely responsible for repairing the kidney. These tubular cells undergo dedifferentiation and morphological changes, migrate along the basement membrane, proliferate, and finally differentiate to restore a functional nephron (11) (12) (13) (14) . Recent evidence and the introduction of more sensitive kidney injury markers have challenged the paradigm that repair is without consequences, demonstrating that, in many cases, the extraordinary ability of the kidney to repair is incomplete, and AKI leads to maladaptive repair with persistent parenchymal inflammation, pericyte/fibroblast proliferation, and excessive deposition of extracellular matrix (10) . We have reported that severe AKI leads to tubular cell cycle arrest in the G 2 -M phase of the cell cycle with secretion of profibrotic factors at least partially mediated by c-Jun N-terminal kinase (JNK) signaling (2) . However, the exact cellular mechanisms involved in secretion of profibrotic factors in G 2 -M-arrested cells are not well understood.
Senescence is a state characterized by chromatin reorganization, cell cycle exit, and the secretion of the senescence-messaging secretome, which includes inflammatory cytokines, modulators of the extracellular matrix, and growth factors (15) . Recently, a new compartment of the senescent cell has been described, named the target of rapamycin (TOR)-autophagy spatial coupling compartment (TASCC) (16) . The TASCC forms from the association of the late autophagosome and the mammalian TOR complex 1 (mTORC1) kinase with the exclusion of Unc-51-like kinase 1 (16) . Organelles are degraded in autophagosomes, releasing amino acids that induce the movement of mTORC1 to the lysosomal membrane (17) . The Ragulator complex interacts with Rag guanosine triphosphatases (GTPases) and tethers Rag heterodimers to the lysosome. The complex is critical for TORC1 kinase activation through Rheb, resulting in increased endoplasmic reticulum (ER)-mediated protein synthesis and increased secretion of proteins (16, 17) . Enhanced protein synthesis increases lysosomal and other membrane proteins, which can refuel the TASCC, leading to a vicious circle. This tightly regulated process is sensitive to any intervention that will disrupt amino acid flux or the localization of mTORC1 to the TASCC (16) . The TASCC structure has been observed in kidney podocytes (16) , but neither its presence nor its role in pathophysiological states in vivo has been described. We hypothesized that the TASCC plays a crucial role in the secretion of profibrotic factors by G 2 -M-arrested PTCs.
RESULTS

TASCC formation is observed in PTCs during kidney fibrosis progression
To investigate whether TASCC formation was involved in the development and/or progression of CKD after AKI, we performed several models of AKI in mice leading to various degrees of fibrosis. As we have previously reported (2) , aristolochic acid (AA) injection (5 mg/kg body weight), 32 min of bilateral renal ischemia reperfusion injury (IRI), or 30 min of unilateral renal IRI (UIRI) led to severe fibrosis in BALB/c mice (Fig. 1A) 21 days after injury. We first explored whether TASCC formation occurred in our models by staining with mTOR, LC3, and LAMP2 antibodies. Whereas TASCC structures were almost undetectable in tubule cells from sham-treated mice (Fig. 1, A and B) , many TASCCs were seen in tubular sections after severe kidney injury (Fig. 1, A and B) . TASCC structures, as shown previously in a lung fibroblast cell line (16) , were also positive for p62 ( fig. S1A ). Using colocalization experiments with Lotus tetragonolobus agglutinin (LTA), a specific marker of differentiated PTCs, and mTOR, we found that TASCCs were mainly expressed in PTCs (Fig. 1C) . To better understand the development of TASCC during CKD, we performed a time course using different models of injury. During the acute phase of injury, at days 2 and 7, there was no statistically significant increase in TASCC + cells (Fig. 1D ). The number of tubular cells expressing TASCC increased progressively starting after day 7 to day 21 after injury and remained high on day 42 ( Fig. 1D) in the three models, AA, severe IRI, and UIRI, that are associated with greater degrees of fibrosis. We confirmed the specificity of our primary antibodies for TASCC components by performing the same experiment with isotype-matched immunoglobulin G (IgG) from each species used in the study ( fig. S1B ).
To better understand the relationship between TASCC + cells and the extent of fibrosis, we included an additional model of AKI that led to less fibrosis (moderate IRI, 30 min of ischemia), and two rescue models of fibrosis (2) including UIRI followed 3 days later by a contralateral nephrectomy, and mice with UIRI that were treated with pifithrin- (PIF-) injection, a p53 inhibitor (Fig. 1, A and D,  and fig. S1C ). TASCCs were seen in PTCs in both models, but fewer were present when compared to severe injury models, which lead to more fibrosis (Fig. 1, A and D, and fig. S1C ).
PTCs arrested in G 2 -M of the cell cycle stain positive for TASCC We next investigated whether TASCC formation was present in G 2 -Marrested proximal tubule cells involved in fibrosis progression (2) . We costained cells with phospho-H3 (pH3) antibody, as a marker of the G 2 -M phase (2), and mTOR antibody ( Fig. 2A) . As we previously reported (2), AA injection and severe bilateral or unilateral IRI lead to an increased number of pH3 + cells. After AA injection, there were fewer pH3 + cells with mTOR staining characteristic of TASCC formation early after AA injection but the number increased progressively so that up to 80% of pH3 + cells on day 42 after injection were also TASCC + (Fig. 2, A and B) . Most of the tubular cells (85%) with mTOR distribution consistent with TASCC formation expressed pH3 (Fig. 2C) .
To further characterize the relationship between the G 2 -M phase of the cell cycle and TASCC formation, we treated two cell lines with characteristics of the proximal tubule, HK-2 and LLC-PK1 cells, with AA. After 48 hours of AA treatment, mTOR and LC3 distribution in the cell was reorganized from a diffuse location to specific punctate regions of the cell typical of a TASCC in both LLC-PK1 cells (Fig. 2, D and E) and HK-2 cells ( fig. S1D ). Western blot analysis revealed an increase in the membrane accumulation of LC3 in AA-treated LLC-PK1 (Fig. 2F and fig. S1D ). To determine the stage of autophagosome maturation in which LC3 was associated with TASCC structures, we transfected ptf-LC3 [encoding a pHsensitive green fluorescent protein (GFP) and pH-resistant red fluorescent protein (RFP) tagged to LC3 (18) ] and treated with AA. TASCC structures, LC3 and mTOR positive, were found to be associated with the RFP, indicating late autophagosomes that have fused with lysosomes (Fig. 2G) . Together, these data suggest that TASCC formation occurs in PTCs arrested in the G 2 -M transition.
We evaluated the link between DNA damage, G 2 -M cell cycle phase, and TASCC formation. We first confirmed, using phosphorylated H2AX (H2AX) immunostaining, that AA induced DNA damage (Fig. 2H) . Most of the cells with DNA damage expressed LC3 in a TASCC pattern (Fig. 2H, right panel) . With DNA damage, coimmunostaining experiments with pH3, mTOR, and LAMP2 revealed that most of the pH3 + cells contained relocalized mTOR and LAMP2 in TASCCs (Fig. 2I and fig. S1E ). Western blot analysis of the supernatant showed that LLC-PK1 and HK-2 cells treated with AA secreted the profibrotic factor, connective tissue growth factor (CTGF), into the culture medium (Fig. 2J) . Thus, PTCs in the G 2 -M phase of the cell cycle after injury express TASCC and secrete the profibrotic factor CTGF.
Cyclin G1 is a key factor during G 2 -M arrest and TASCC formation
To elucidate the molecular pathways of G 2 -M arrest and TASCC formation induced by AA, we performed an unbiased profiling of gene expression data ( fig. S2A ). We interrogated microarray data comparing the complementary DNA profiles in the kidneys of rats administered either vehicle or AA (10 mg/kg), five times per week by oral gavage, for 12 weeks (19) . RNA was isolated and compared across five different microarray platforms (Affymetrix 1, 2, GE Healthcare, ABI, and Agilent) from Gene Expression Omnibus (GEO) (series accession number GSE5350). We found 47 genes whose expression differed significantly on all platforms after AA injection (P < 0.001) (19) . Grouping these results by gene ontology category, we observed a range of functions for the 47 transcripts, including cell cycle-apoptosis, development, metabolism, and cell proliferation. Ingenuity Pathway Analysis (IPA) revealed that the top two pathways up-regulated by AA were the glutathione detoxification pathway and the p53 pathway ( fig. S2B ). Previously, we reported that the p53 pathway contributes to G 2 -M arrest and fibrosis in several animal models of kidney fibrosis (2) . The p53 pathway genes most highly up-regulated in this study were CDKN1A (p21), BBC3 (PUMA), and Ccng1 (cyclin G1) ( fig. S2B ). Of these, cyclin G1 is known to directly regulate G 2 -M arrest (20) .
Cyclin G1 (CG1) is an atypical cyclin, regulated at the transcriptional level by p53, whose functions have not been clearly elucidated. CG1 is involved in the arrest of cell cycle progression through G 2 -M phase and is induced by DNA damage (20, 21) . Western blot analysis confirmed at the protein level the dramatic increase of CG1 21 days after injury induced either by AA or by severe bilateral or unilateral IRI (Fig. 3A) . Animal models in which kidney fibrosis had been mitigated through p53 inhibition (UIRI + PIF-) or through removal of the contralateral kidney after UIRI (UIRI + Nx day 3) had lower expression of CG1 (Fig. 3A) . To better understand its role, we then imaged the colocalization of CG1, pH3, and LAMP2 in damaged kidneys. CG1 was mainly expressed in proximal tubule cells that were pH3 + , and CG1 + cells also correlated with LAMP2 staining, consistent with TASCC formation (Fig. 3B) . To corroborate our findings, we performed experiments in vitro, treating HK-2 To further decipher the relationship between CG1, G 2 -M arrest, and TASCC formation, we transfected HK-2 cells with CG1 ( . To test whether CG1 induced G 2 -M arrest directly, we transfected LLC-PK1 cells with CG1, pulsed with 5-bromo-2′-deoxyuridine (BrdU) for 3 hours, and fixed cells 8 hours after the pulse. We found that the number of cells double positive for BrdU and pH3 after the pulse chase was significantly increased in hCG1-transfected cells (P = 0.0013) (Fig. 3E ). pH3 + CG1-transfected cells also stained positive for TASCC (mTOR and LAMP2) (Fig. 3F ). In addition, transfection with CG1 led to an increased production of profibrotic cytokines, including transforming growth factor-1 (TGF-1) in cell lysates ( Fig. 3G and fig. S3C ), and CTGF secretion into supernatants (Fig. 3H) , even in the absence of the CG1 regulator p53 (Fig. 3I) . The production of TGF-1 was enhanced by sublethal injury with AA (10 g/ml) but not with lethal injury via AA (20 g/ml) (Fig. 3G) . Thus, CG1 plays a role in increasing the number of cells in G 2 -M, TASCC formation, and profibrotic factor production/secretion.
CG1 and TASCC are increased in G 2 -M phase cells in a model of liver fibrosis
To determine whether the increases in CG1 and TASCC formation were specific for kidney fibrosis progression, we administered vehicle (mineral oil) or carbon tetrachloride (CCl 4 ) to mice three times per week for 12 weeks. CCl 4 is a toxin well known to induce liver fibrosis (22) . As expected, CCl 4 administration was associated with the development of liver fibrosis, particularly surrounding the central vein (Fig. 4A ). CCl 4 administration was associated with a greater number of pH3
+ cells compared to vehicle-treated animals (Fig. 4 , B and D). Whereas TASCC + cells were barely detectable in the liver of the vehicle-treated group, about 55% of the pH3 + cells were also TASCC + after CCl 4 administration (Fig. 4 , B and D). Furthermore, whereas CG1 was not detectable in the liver of the vehicle-treated group, it was induced in the liver after CCl 4 administration and colocalized with TASCC + G 2 -M phase cells (Fig. 4, C and D) . Hence, increased CG1 expression is associated with an increase in the number of G 2 -M phase cells, TASCC formation, and liver fibrosis.
CG1 and G 2 -M arrest promote PTC dedifferentiation G 2 -M arrest is associated with a number of phenotypes, including dedifferentiation, senescent-like changes, cell size changes, and increased secretion of proinflammatory and profibrotic cytokines in kidney cells as well as other cell types (23) (24) (25) . To determine whether CG1-associated G 2 -M arrest promotes dedifferentiation phenotypes, we analyzed differentiation markers in LLC-PK1 cells treated with AA or transfected with CG1. AA treatment induced an increase in cell size (fig. S3, D and E), significantly reduced ZO-1 expression in LLC-PK1 cells, and promoted vimentin expression ( fig. S3F ). hCG1 transfection led to decreased expression of Na/K-ATPase (adenosine triphosphatase), which is normally highly expressed in PTCs (Fig. 5A) , and increased expression of vimentin, when combined with AA treatment (Fig. 5B) . These data suggest that AA-or CG1-induced cell cycle changes promote dedifferentiation of PTCs. To test whether CG1 induced a senescent-like state, we tested whether CG1 knockout reduced -galactosidase (-gal) activity. Wild-type mouse primary PTCs treated with AA demonstrated an about fivefold increase in -gal staining compared to wild-type cells treated with PBS. CG1 −/− cells had no increase in -gal staining with AA treatment (Fig. 5C ).
Preventing TASCC formation reduces profibrotic factor secretion Next, we determined whether targeting TASCC activity could decrease fibrosis. In response to amino acid release, mTORC1 is recruited to the membrane of the lysosome through the Rag GTPase complex (26, 27) . Dominant negative forms of Rag GTPase can disrupt the recruitment of mTORC1 to the lysosome upon amino acid stimulation (26, 27) . A dominant negative form of RagB has been shown to disrupt the recruitment of mTORC1 to the TASCC and reduce interleukin-6/8 production in oncogene-induced senescence cells (16) . To explore the relevance of these findings to our models, we transfected LLC-PK1 cells with EV, hCG1, the dominant negative form of RagB (RagB DN), or hCG1 + RagB DN and exposed them to AA. LLC-PK1 cells transfected with EV and exposed to AA secreted CTGF (Fig. 5D) . LLC-PK1 cells transfected with hCG1 spontaneously secreted CTGF (Fig. 5D) . Transfection of LLC-PK1 cells with hCG1 increased the number of cells in the G 2 -M phase of the cell cycle (Fig. 5E ). LLC-PK1 cells transfected with the RagB DN secreted less CTGF in response to AA (Fig. 5D) . To further characterize the role of CG1 during TASCC formation, we cotransfected LLC-PK1 cells with hCG1 and RagB DN and exposed cells to AA or diluent. Although there was an increase in the number of cells in G 2 -M, the cotransfected cells (hCG1 + RagB DN) treated with AA produced less CTGF when compared to cells treated with EV (Fig. 5,  D and E) . Coimmunostaining experiments revealed that LLC-PK1 cells transfected with RagB DN and exposed to AA did not form TASCC (Fig. 5, F and G) . Thus, mTORC1 recruitment was important for the production of TASCC in cells treated with AA. In addition, these experiments suggest that targeting the TASCC would reduce fibrotic factor synthesis.
TASCC blockade is protective against fibrosis progression
Next, we tested whether targeting the TASCC in vivo could be a potential therapeutic approach to prevent kidney fibrosis progression. Rapamycin or everolimus, two mTOR inhibitors, have been reported to either exacerbate (28, 29) or improve (30-32) fibrosis and tubular dilation in different mouse models of CKD. Introducing these inhibitors early after the injury (28) is associated with worsening kidney lesions, whereas administration later is associated with improvement of fibrosis and tubular dilation (30, 32) . We hypothesized that rapamycin would interfere with normal repair when they are injected early after injury, whereas their injection later would target both mTORC1 and mTORC2 and hence inhibit TASCC formation in G 2 -M cells (33) (34) (35) .
To avoid potential complications with small molecule inhibitors, we used a genetic approach to specifically block TASCC formation in the proximal tubule after injury. Raptor is a major component of the mTOR complex 1. We bred Raptor flox/flox mice with Slc34a1-GFPCreER T2 (Slc34a1 ; Raptor flox/flox mice not treated with tamoxifen are designated Raptor flox/flox . Prolonged bilateral renal IRI (32 min) was carried out in mice with or without tamoxifen injection (3 doses every other day) to induce Cre expression initiated either 7 days before injury or day initiated 21 after injury, and examined tissue 42 days after injury. We first confirmed that Cre recombination was efficient in reducing raptor expression in the kidney cortex by immunocytochemistry, confirming deletion of raptor in most of the LTA + PTCs (Fig. 6A) . Western blot analysis of whole-kidney lysates revealed significantly less raptor expression after Cre recombination (P < 0.001) (Fig. 6B) . Raptor PT mice with Cre recombination 7 days before IRI had worse kidney function with higher blood urea nitrogen (BUN) values at day 42 (Fig. 6C) (P < 0.001) or Raptor PT d−7 mice treated with Cre recombination 7 days before IRI (P < 0.001). Consistently, Raptor PT mice with Cre recombination 21 days after IRI had a lower expression of fibrosis markers [-smooth muscle actin (SMA), fibronectin, and COL4A1 mRNA] and less fibrosis as assessed histologically (Fig. 6, D to F) . Coimmunostaining experiments in tissue from mice sacrificed on day 42 after renal IRI showed fewer TASCCs in Raptor PT d+21 mice compared with the control wild-type Raptor flox/flox mice not treated with tamoxifen ( fig. S4, A and B) . As expected, the percentages of PTCs staining for BrdU and pH3 were similar in the two groups of mice, indicating that disrupting Raptor did not alter G 2 -M arrest ( fig. S4C ). Likewise, we observed an up-regulation of CG1 expression in both Raptor flox/flox and Raptor PT after IRI, again demonstrating that loss of Raptor did not interfere with upstream signaling pathways, which promote G 2 -M arrest (fig. S4D) (Fig. 6G ), reduced expression of fibrotic markers, and a lower kidney fibrosis score (Fig. 6, H to J) . These data show that inhibition of the formation of TASCC in PTCs in vivo reduces kidney fibrosis progression after injury.
Deletion of CG1 inhibits TASCC formation and fibrosis
To determine the role of CG1 in kidney fibrosis progression, we induced kidney injury in CG1 −/− mice by AA injection and monitored TASCC formation and kidney fibrosis 6 weeks after injection. CG1 −/− mice had reduced protein expression of the kidney injury marker KIM-1 6 weeks after AA injection (Fig. 7, A and B) . As expected, CG1 −/− mice also had a reduced percentage of pH3 + G 2 -M phase cells (Fig. 7C) . Kidney injury, as measured by serum creatinine, was similar between wild-type and CG1 knockout mice during the acute phase of injury (Fig. 7D) . Next, we analyzed TASCC formation in CG1 −/− mice by quantifying the colocalization of LC3, LAMP2, and mTOR using Pearson's correlation. TASCC formation was significantly reduced in kidneys from CG1 −/− compared to wild-type mice (P < 0.05) (Fig. 7 , E and F). With AA treatment, kidney fibrosis was about 50% less in CG1 −/− mice compared to wild-type mice, as measured by quantification of polarized images of picrosirius red and Masson's trichrome stainings (Fig. 7, G to I) . CG1 −/− mice also had reduced SMA, TGF-, and CTGF mRNA after AA-induced injury (Fig. 7, J to L) . These data indicate that CG1 regulates G 2 -M arrest and subsequent TASCC formation in vivo, ultimately contributing to kidney fibrosis progression.
TASCC formation is increased in G 2 -M phase cells in patients with CKD
We evaluated the relevance of our findings using tissue samples from 5 control patients, 10 with AKI, and 40 with CKD of various etiologies including chronic interstitial nephritis (n = 10), AA nephropathy (n = 10), diabetic kidney disease (DKD) (n = 10), and hypertension nephropathy (n = 10) (table S1). Using colocalization studies on human kidney biopsy tissue, we quantitated the number of tubular cells that contained TASCC per field (40×) (Fig. 8, A and B) and the number of pH3 + tubular cells that contained TASCC per 40× field (Fig. 8, C  and D and fig. S5 ) and compared the findings to controls (n = 5). TASCC formation was enriched in cells in the G 2 -M phase of the cell cycle in each of the disease groups (Fig. 8D ). There was a correlation between TASCC + tubular cells and fibrosis (R 2 = 0.615, P = 0.008) but not with urine albumin/creatinine ratio ( fig. S5 , B and C).
DISCUSSION
By combining several experimental models of AKI to CKD transition in mice, studies with epithelial cells in vitro, unbiased gene expression analyses and validation in human biopsies, we identified a mechanism of kidney fibrosis development and progression. As we previously reported, after injury that ultimately leads to fibrosis, a certain percentage of PTCs are arrested in the G 2 -M phase of the cell cycle (2) . These cells participate in maladaptive repair by secreting profibrotic factors with potential auto-and paracrine effects. Here, we show that CG1 induction is sufficient to increase the number of cells in the G 2 -M phase and that a high percentage of cells in the G 2 -M phase have TASCCs, structures previously described in Ras-induced senescent cells (16) . Inhibition of TASCC formation results in less kidney fibrosis after injury, thus identifying a potential new therapeutic target. Furthermore, we confirmed that these findings are relevant to human CKD.
Our study reveals that increased TASCC formation is associated with synthesis and secretion of profibrotic factors, similar to the senescence-messaging secretome, leading to fibrosis and its progression. Secreted factors may potentiate cell cycle arrest in G 2 -M (2, 24) . Some tubular cells expressing the TASCC were not in G 2 -M, but were in the close vicinity of pH3 + cells. These results are in accordance with recent findings showing that the senescence of one cell can be transmitted by secretory paracrine mechanisms to neighboring cells (37) .
We found that TASCC formation was mediated through CG1 induction. CG1 is an atypical cyclin whose precise roles are unknown. It interacts with p53 and p21, two cyclin-dependent kinase inhibitors playing a role in G 2 -M arrest and kidney fibrosis progression (2, (38) (39) (40) (41) . CG1 is induced by DNA damage (42) and promotes G 2 -M arrest (20, 43) . In kidney epithelial cells in culture, the overexpression of cyclin G1 was sufficient to induce G 2 -M arrest, TASCC formation, and profibrotic factor secretion. Deletion of CG1 prevented G 2 -M arrest, inhibited TASCC formation, and reduced kidney fibrosis after injury. Although CG1 was up-regulated and there was an increased number of cells at the G 2 -M transition in the cell cycle in Raptor PT mice after IRI, TASCC formation was not detectable and fibrosis was reduced, reinforcing that the profibrotic events downstream of CG1-facilitated G 2 -M arrest are mediated by TASCC formation. Furthermore, we demonstrated that this process is not unique to the kidney and may represent a common process of fibrosis progression, because it was also detectable in fibrotic liver.
AKI is marked by dramatic injury and loss of kidney tubular cells, especially in the proximal tubule. As part of this repair process after kidney injury, it is known that PTCs undergo dedifferentiation to migrate, alter their morphology, and divide to reform the damaged tubule segments (9, 11, 12, 14, 24, 44, 45) . We found evidence of increased cell size, reduced differentiation marker expression, increased dedifferentiation marker (vimentin), and increased senescence in PTCs overexpressing CG1 or treated with AA. It is particularly interesting that CG1 overexpression alone mimicked dedifferentiation characteristics observed in injured PTCs and enhanced the effects of injury on dedifferentiation. It is unlikely that CG1-induced G 2 -M arrest regulates dedifferentiation, because PTCs must dedifferentiate early in the process of entering the cell cycle. CG1 has been reported to regulate epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma cell lines through SNAIL stabilization (46) . Together, these data suggest a role for CG1 expression in regulating the dedifferentiation status of PTCs. TASCC blockade is sufficient to reduce the severity of kidney fibrosis progression. In vitro, we confirmed that cells transfected with a dominant negative RagB construct have reduced synthesis of fibrotic factors. Dominant negative RagB is not able to recruit mTORC1 to the lysosome membrane, preventing TASCC formation. In vivo, genetic deletion of raptor in PTCs, performed 21 days after bilateral IRI, reduced the kidney fibrosis score 42 days after IRI. This may explain the apparent discrepancy of the impact of mTORC inhibitor administration in mouse models of nephron reduction (28) . Exposure to mTORC inhibitors early after injury leads to severe renal lesions related to inhibition of the normal repair process (28) , whereas late administration improves kidney lesions (30, 32) , potentially due to TASCC blockade and inhibition of secretion of profibrotic growth factors and cytokines in G 2 -M-arrested cells involved in the maladaptive repair. TASCC formation was also seen in humans with kidney disease. We studied a group of patients with various causes of CKD that developed progressive fibrotic lesions. Compared to controls, kidney tissue with fibrosis contained more PTCs in the G 2 -M phase of the cell cycle, and these cells expressed TASCCs. We also found TASCC + cells in patients with AKI. Although the biopsies are from patients with AKI, they can be expected to be derived at varying times after the initiation of the insult or insults and most patients with AKI will have some degree of underlying CKD or progress to CKD.
In conclusion, we have identified a mechanism of fibrosis progression involving the induction of CG1-promoted TASCC formation, which facilitates profibrotic factor secretion in cells in the G 2 -M phase of the cell cycle. This pathway may represent a new promising therapeutic target.
MATERIALS AND METHODS
Study design
The objective of this study was to determine the underlying cause of G 2 -M arrest and profibrotic secretory phenotypes in kidney epithelial cells that promote kidney fibrosis. Using a systems biology approach, we identified the p53 pathway, and in particular CG1, as the most likely pathway regulating G 2 -M arrest and senescence-like phenotypes in kidney fibrosis. We hypothesized that CG1 induces G 2 -M arrest in kidney tubule epithelial cells, contributing to (senescenceassociated) TASCC formation and secretion of profibrotic cytokines. To test this hypothesis, we designed a study using human tissue, multiple models of kidney injury in normal mice, mice deficient in CG1 or components of the TASCC, and in vitro models of tubular cell injury to determine the role of CG1 and TASCC in CKD. We selected sample sizes to have 80% power to detect a 50% reduction in fibrotic area (as calculated by power analysis using Student's t test) based on data from wild-type mice and past experience with models of kidney injury in mice. Inclusion/exclusion criteria were kept to a minimum and established before any quantification. For animal studies, as much as possible, we used littermates, which facilitates appropriate randomization. Within the littermate groups, animals were selected at random for IRI or sham surgeries. The IRI surgery was performed by an investigator who was not aware of the genotype or experimental assays to be performed after the surgery. For studies with AA, animals from each genotype were chosen at random, within littermates, for the vehicle or treatment groups. For in vitro studies, a minimum of three experimental replicates was performed. The number of replicates is indicated in the figure legends. For all cell experiments in vitro, equal numbers of cells were plated. Processing was performed simultaneously and in parallel for all conditions within each experiment. Human samples were carefully evaluated by two independent pathologists. Statistical tests were chosen based on nature of variables, assumption of data distribution, and effect size. In general, continuous data were analyzed by Student's t test, Mann-Whitney test, or ANOVA. False discovery rate was controlled by conducting at least three independent experiments. In the case of multiple comparisons, Tukey's post hoc test was used. Primary data are reported in data file S1.
Animals
Kidney models of injury
Mice were male BALB/c and C57BL/6 mice, aged 8 to 10 weeks (20 to 22 g), purchased from Charles River Laboratories. Raptor flox/flox mice on a C57BL/6 background were purchased from the Jackson Laboratory. CG1 −/− mice were provided by S. Thorgeirsson at the National Cancer Institute, National Institutes of Health, USA.
Ischemia was induced by the retroperitoneal approach on both kidneys for 30 min at 37.0°C (moderate IRI, n = 24 mice) or for 32 min at 37.5°C (severe IRI, n = 24) or only the left kidney for 30 min at 37°C (unilateral IRI, n = 24) in BALB/c mice, as previously reported (2) . For the UIRI model, two approaches were taken in several groups of mice: Nephrectomy of the contralateral kidney was performed 3 days after UIRI surgery (n = 24 mice) or mice were given PIF- (2.2 mg/kg body weight, Sigma), dissolved in phosphate-buffered saline (PBS), intraperitoneally on days 3 and 14 after UIRI surgery (n = 24). PBS was injected in the control groups. One milliliter of warm saline (37°C) was injected intraperitoneally after all surgeries for volume supplement. Sham operations were performed with exposure of both kidneys but without induction of ischemia. AAN was induced in BALB/c mice by a one-time intraperitoneal injection of AA (5 mg/kg body weight, Sigma) in PBS (n = 36 mice). The normal control mice were administered the same amount of PBS (n = 24). ) and 12 Raptor PT adult (8-to 10-week-old) mice. Cre recombinase was induced either 7 days before ischemia or on day 21 after IRI by intraperitoneal injection of tamoxifen (300 g, SigmaAldrich) to mice every other day, for a total of three times. Deletion using Slc34A1 CGE/+ has been shown to occur within 1 week of tamoxifen injection (36) . Tamoxifen (Sigma-Aldrich) was dissolved in 3% (v/v) ethanol containing corn oil (Sigma-Aldrich). Slc34a1GCE expression was up-regulated before tamoxifen injection by feeding mice a low-phosphorus (0.06%) diet (TestDiet) (36) . In all cases, littermate control phenotypes were compared.
Conditional Raptor knockout
AA injury was induced in 10-to 12-week-old male Raptor flox/flox and Raptor flox/flox :SLC34a1GCE mice or CG1 −/− and wild-type mice which are on a C57BL/6 background. AA (Sigma) was administered to mice intraperitoneally (3 mg/kg body weight) every other day for three times. Eleven days after the last dose of AA injection, three doses of tamoxifen (300 g) were injected every other day (36) . Mice were sacrificed 5 weeks after the last dose of AA.
Animals were fed ad libitum and housed at constant ambient temperature in a 12-hour light cycle. All animal experiments were performed in accordance with the animal use protocol approved by the Institutional Animal Care and User Committee of Harvard Medical School, the Institutional Animal Care and User Committee of Vanderbilt University Medical Center, and the Institutional Review Board of Tokushima University Graduate School for Animal Protection. Liver models of injury C57BL/6 male mice received either vehicle (mineral oil) or CCl 4 (Sigma) (n = 6 mice per group) by oral gavage three times per week for 12 weeks according to an escalating dose protocol (first dose, 0.875 ml/kg; weeks 1 to 3, 1.75 ml/kg; weeks 4 to 6, 2.5 ml/kg; weeks 7 to 12, 3.25 ml/kg) as previously described (47) .
Cell culture
The HK-2 (human) and LLC-PK1 (pig) proximal cell lines were cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% fetal calf serum (FCS) until the cells were 80% confluent. Cells were then incubated in DMEM containing 0.2% FCS for 24 hours. After growth factor deprivation, cells were treated with AA (5-20 g/ml) in full medium (DMEM with 10% FCS) for 48 hours. Conditioned medium was then collected, and the cells were collected by either trypsinization, for flow cytometry, or lysed in 1× sample buffer [50 mM tris-HCl (pH 6.8), 10% glycerol, 2% SDS, and 12.5 mM EDTA] for immunoblot analysis.
Immunofluorescence
Cultured cells were fixed in 4% paraformaldehyde for 20 min, permeabilized in PBS containing 0.2% Triton X-100 and 3% bovine serum albumin, and incubated with primary antibodies to the indicated protein of interest, followed by Alexa Fluor-conjugated secondary antibodies (Jackson ImmunoResearch).
For human kidney biopsies and mouse kidney samples, 4-m sections of paraffin-embedded kidneys were submitted to antigen retrieval protocols using high temperature (120°C) and high pressure in citrate buffer and a pressure cooker. Sections were then incubated with primary antibodies as indicated and appropriate Alexa Fluor-conjugated secondary antibodies (Jackson ImmunoResearch). Immunofluorescence for human tissue was performed on n = 10 kidney tissue per group of renal disease and n = 5 controls. The control group was composed of healthy renal peritumoral tissues. Renal function and albumin/creatinine ratio were determined at the time of biopsy.
Fibrosis quantification
Kidney sections were stained with Masson's trichrome or picrosirius red and quantified using Nikon NIS Elements software or scored by an experienced pathologist in a blinded manner. Briefly, mouse kidney sections were stained using Masson's trichrome, a mixture of three dyes including aniline blue that is specific to collagen fibers, at the Brigham and Women's Hospital Pathology Core (48) . The collagenpositive area was quantified using NIS Elements software. Other mouse kidney sections were stained with picrosirius red (EMS) using the manufacturer's protocol, and whole-kidney sections were imaged at ×10 magnification, stitched images, under polarized light. Positive area was quantified using NIS Elements software. Picrosirius red staining binds specifically to collagen and increases the birefringence properties of the collagen fibers, when observed by polarized light microscopy (49) . The renal papilla was omitted from quantification as it contains collagen-rich vascular structures, which skew the results. Human kidney samples were assessed using trichrome staining. The slides were reviewed in a blinded manner by two pathologists and were graded using quantitative image analysis. Results were expressed as a percentage of fibrosis and scored (grade I, <25%; grade II, 26 to 50%; grade III, >50%).
Antibodies
The following primary antibodies were used for immunofluorescence or Western blot.
Immunofluorescence: mTOR (Cell Signaling Technology, rabbit, 1:50), LC3 (Nanotools, mouse, 1:50), LAMP2 (Developmental Studies Hybridoma Bank at the University of Iowa, rat, GL2A7, 1:25), vimentin (Developmental Studies Hybridoma Bank at the University of Iowa, mouse, 1:50), CG1 (Santa Cruz Biotechnology, rabbit, 1:50), LTA (Vector Laboratories), Ki-67 (Vector Laboratories, rabbit, 1:50), and pH3 (Cell Signaling Technology, mouse, 1:50).
Western blot: CTGF-specific antibody (GeneTex, 1:1000), rabbit antibody to CG1 (Santa Cruz Biotechnology, 1:500), mouse antibody to LC3 (Nanotools, 1:500), rabbit antibody to extracellular signal-regulated kinase (ERK) (Cell Signaling, 1:1000), rabbit antibody to Raptor (Cell Signaling, 1:500), rabbit antibody to TGF- (Cell Signaling, 1:500), Na + /K + -ATPase (Developmental Studies Hybridoma Bank at the University of Iowa, mouse, 1:50), and rabbit antibody to -actin (Sigma, 1:5000).
Statistical analysis
Statistical analyses were performed using Prism 6.07 (GraphPad Software Inc.). All results are reported as means ± SEM. Statistical tests are two-tailed, unpaired Student's t tests and one-way ANOVA followed by Tukey's post hoc test. A P value of <0.05 was interpreted as statistically significant. In general, normal distribution was assumed with a sample size of n > 30. In case nonparametric test showed lack of power and robustness in a smaller sample size, parametric test and strict control of the false discovery rate were applied.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/11/476/eaav4754/DC1 Materials and Methods Fig. S1 . TASCC formation in vitro and in vivo. Fig. S2 . Microarray analysis reveals link between p53 signaling, CG1, and fibrosis. Fig. S3 . AA treatment induced cell damage, up-regulation of vimentin, and decreased expression of ZO-1. Fig. S4 . Characterization of the Raptor PT mice. Table S1 . Demographic and clinical characteristics of patients from whom kidney tissue was obtained. Data file S1. Primary data. References (50, 51) 
